IL-1β, which triggers a series of inflammatory reactions and bone resorption, has become a therapeutic target for autoimmune and autoinflammatory diseases such as rheumatoid arthritis, gout and type II diabetes mellitus in addition to periodontitis [28]. Here, IL1B is linked to rheumatoid arthritis.